ECSP16087271A - PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES - Google Patents

PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES

Info

Publication number
ECSP16087271A
ECSP16087271A ECIEPI201687271A ECPI201687271A ECSP16087271A EC SP16087271 A ECSP16087271 A EC SP16087271A EC IEPI201687271 A ECIEPI201687271 A EC IEPI201687271A EC PI201687271 A ECPI201687271 A EC PI201687271A EC SP16087271 A ECSP16087271 A EC SP16087271A
Authority
EC
Ecuador
Prior art keywords
pyrazolopyridines
pyrazolopyrimidines
please see
see attached
attached
Prior art date
Application number
ECIEPI201687271A
Other languages
Spanish (es)
Inventor
Gavin Alistair Whitlock
Christoph Martin Dehnhardt
Jotham Wadsworth Coe
Joseph Walter Strohbach
Yogesh Anil Sabnis
Peter Jones
Florian Michel Wakenhut
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53264695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16087271(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP16087271A publication Critical patent/ECSP16087271A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)

Abstract

fAVOR VER ADJUNTOPlease see attached

ECIEPI201687271A 2014-05-14 2016-11-11 PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES ECSP16087271A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461993138P 2014-05-14 2014-05-14

Publications (1)

Publication Number Publication Date
ECSP16087271A true ECSP16087271A (en) 2018-05-31

Family

ID=53264695

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201687271A ECSP16087271A (en) 2014-05-14 2016-11-11 PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES

Country Status (29)

Country Link
US (2) US9518052B2 (en)
EP (1) EP3143021B1 (en)
JP (1) JP6663857B2 (en)
KR (1) KR20170002623A (en)
CN (1) CN106459048A (en)
AP (1) AP2016009562A0 (en)
AR (1) AR100438A1 (en)
AU (1) AU2015260905A1 (en)
CA (1) CA2948587C (en)
CL (1) CL2016002888A1 (en)
CR (1) CR20160525A (en)
CU (1) CU20160167A7 (en)
DO (1) DOP2016000298A (en)
EA (1) EA201650029A1 (en)
EC (1) ECSP16087271A (en)
ES (1) ES2737696T3 (en)
GE (2) GEP20186921B (en)
IL (1) IL248970A0 (en)
MD (1) MD20160121A2 (en)
MX (1) MX2016014878A (en)
NI (1) NI201600170A (en)
PE (1) PE20161475A1 (en)
PH (1) PH12016502228A1 (en)
SG (1) SG11201609139WA (en)
SV (1) SV2016005318A (en)
TN (1) TN2016000503A1 (en)
TW (1) TWI591067B (en)
UY (1) UY36121A (en)
WO (1) WO2015173683A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403810B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
EP3143021B1 (en) 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines
EP3371184A1 (en) 2015-11-03 2018-09-12 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
KR20180073687A (en) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 JAK kinase inhibitor compounds for the treatment of respiratory diseases
ES2840650T3 (en) 2015-11-03 2021-07-07 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo [4,5-c] pyridine and 1,4,5,6,7,8-hexahydroimidazo [4,5-d] azepine derivatives as kinase inhibitors janus
EA037748B1 (en) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Fused imidazo-piperidine jak inhibitors
AR111495A1 (en) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc FUSIONED IMIDAZO-PIPERIDINE COMPOUNDS AS JAK INHIBITORS
MY200348A (en) 2017-05-01 2023-12-21 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound
SG11201909019SA (en) 2017-05-01 2019-10-30 Theravance Biopharma R&D Ip Llc Methods of treatment using a jak inhibitor compound
US10392368B2 (en) 2017-08-01 2019-08-27 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
BR112020008850A2 (en) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. compound, pharmaceutical composition and method for treating a disease mediated by jak1 and jak3
CN112823005B (en) 2018-08-10 2024-08-20 阿克拉瑞斯治疗股份有限公司 Pyrrolopyrimidine ITK inhibitors
CN110833555B (en) * 2018-08-15 2023-03-24 广西梧州制药（集团）股份有限公司 Use of pyrazolopyrimidine derivatives for the treatment of ulcerative colitis
US10836763B2 (en) 2018-09-04 2020-11-17 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
KR102826491B1 (en) 2018-09-04 2025-06-27 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Dimethylamino azetidine amide as a JAK inhibitor
BR112021004087A2 (en) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc process for preparing jak inhibitors and their intermediates
JP2022506111A (en) 2018-10-29 2022-01-17 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 2-Azabicyclohexane compound as a JAK inhibitor
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
SI3932919T1 (en) 2019-02-25 2024-09-30 Henan Medinno Pharmaceutical Technology Co., Ltd. Jak inhibitor compound and use thereof
CN114075199B (en) * 2020-08-14 2026-03-10 河南迈英诺医药科技有限公司 JAK inhibitor compounds and their uses
CN114075200A (en) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 JAK inhibitor compounds for the treatment of severe pneumonia
KR20220004726A (en) 2019-05-02 2022-01-11 어클라리스 쎄라퓨틱스, 인코포레이티드 Substituted pyrrolopyridines as JAK inhibitors
WO2021022178A1 (en) * 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors
EP4071145B1 (en) * 2019-12-30 2025-01-08 Liang Lu Jak inhibitor compound and use thereof
KR20220140515A (en) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. Substituted pyrazolo-pyrimidines and uses thereof
CN113101975B (en) * 2020-01-13 2022-04-22 万华化学集团股份有限公司 Multi-phosphine ligand catalyst system and application thereof in ethylene oligomerization reaction
TW202144343A (en) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Crystalline hydrate of a jak inhibitor compound
CN111548269B (en) * 2020-04-29 2023-10-27 兰州大学 Preparation method of diarylmethane structural compound
GB202010408D0 (en) * 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
CN116438200A (en) 2020-09-10 2023-07-14 普雷西里克斯公司 Antibody fragments against FAP
TW202317550A (en) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 Imidazolo indazole compounds as jak inhibitors
CN115557947B (en) * 2021-07-02 2024-04-02 成都百裕制药股份有限公司 Pyrazolo [4,3-c ] pyridine derivative and application thereof in medicine
CN113480543B (en) * 2021-07-07 2022-05-17 无锡市第二人民医院 2,6, 8-polysubstituted imidazo [1,2-a ] pyrazine and synthetic method and application thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (en) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ Pre-targeting
WO2025217560A1 (en) * 2024-04-12 2025-10-16 Theravance Biopharma R&D Ip, Llc Triazolo indazole compounds as jak inhibitors
WO2025240333A1 (en) * 2024-05-13 2025-11-20 The Texas A&M University System Jak3 targeted smart drugs and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (en) 1990-01-23 1999-01-15 . Cyclodextrin derivatives with increased water solubility and uses thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
AR042064A1 (en) 2002-11-19 2005-06-08 Takeda Pharmaceutical AMINA COMPOUNDS WITH INHIBITING ACTIVITY OF THE UNION TO THE SOMASTOTINE RECEIVER
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
CN101883774A (en) * 2007-10-16 2010-11-10 惠氏有限责任公司 Thienopyrimidine and pyrazolopyrimidine compounds and their use as MTOR kinase and PI3 kinase inhibitors
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009070524A1 (en) * 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
CN102014914A (en) * 2008-01-15 2011-04-13 惠氏有限责任公司 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as MTOR kinase and PI3 kinase inhibitors, and their syntheses
ES2494365T3 (en) * 2008-01-30 2014-09-15 Genentech, Inc. Pyrazolopyrimidine compounds that inhibit PI3K and methods of use
ES2566339T3 (en) * 2008-06-05 2016-04-12 Glaxo Group Limited 4-Carboxamide indazole derivatives useful as PI3-kinase inhibitors
WO2009153261A1 (en) * 2008-06-18 2009-12-23 Solvay Pharmaceuticals Gmbh HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS
WO2010058846A1 (en) 2008-11-21 2010-05-27 アステラス製薬株式会社 4,6-diaminonicotinamide compound
MX2011009807A (en) * 2009-03-19 2011-09-29 Medical Res Council Technology Compounds.
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP3143021B1 (en) 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines

Also Published As

Publication number Publication date
AU2015260905A1 (en) 2016-12-01
GEAP201814322A (en) 2018-07-25
CN106459048A (en) 2017-02-22
DOP2016000298A (en) 2018-04-30
IL248970A0 (en) 2017-01-31
CA2948587A1 (en) 2015-11-19
AR100438A1 (en) 2016-10-05
EP3143021A1 (en) 2017-03-22
TN2016000503A1 (en) 2018-04-04
UY36121A (en) 2016-01-08
MX2016014878A (en) 2017-03-08
WO2015173683A1 (en) 2015-11-19
PE20161475A1 (en) 2017-01-08
CA2948587C (en) 2018-07-17
EA201650029A1 (en) 2017-09-29
US9518052B2 (en) 2016-12-13
SG11201609139WA (en) 2016-11-29
TWI591067B (en) 2017-07-11
CL2016002888A1 (en) 2017-05-12
EP3143021B1 (en) 2019-06-12
MD20160121A2 (en) 2017-05-31
TW201546071A (en) 2015-12-16
US20150329542A1 (en) 2015-11-19
KR20170002623A (en) 2017-01-06
JP6663857B2 (en) 2020-03-13
CU20160167A7 (en) 2017-04-05
JP2017515836A (en) 2017-06-15
GEP20186921B (en) 2018-11-12
US20170071946A1 (en) 2017-03-16
AP2016009562A0 (en) 2016-11-30
US10022376B2 (en) 2018-07-17
NI201600170A (en) 2017-01-03
ES2737696T3 (en) 2020-01-15
SV2016005318A (en) 2017-03-06
PH12016502228A1 (en) 2017-01-09
CR20160525A (en) 2016-12-20

Similar Documents

Publication Publication Date Title
ECSP16087271A (en) PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES
NL301227I2 (en) Table ecleucel
DK3237418T3 (en) Triazolopyrimidine Compounds and uses thereof
ECSP17015977A (en) COMBINATION THERAPY
GB2524093B (en) Light fixture
GB201402290D0 (en) Fixture
EP3122256C0 (en) RADIOTHERAPY PANEL AND TABLE
DK3129006T3 (en) Immunosuppressive formulation
ECSP17014972A (en) AZETIDINYLOXPHENYLPYRROLIDINE COMPOUNDS
DK3119979T3 (en) CENTERING DEVICE
ECSP17050310A (en) CICLOPROPABENZOFURANIL-PYRIDOPYRAZINDIONAS NOVEDOSAS
DE112015003475A5 (en) chuck
DE112015002149A5 (en) lighting device
LT3512849T (en) 7-SUBSTITUTED 1-ARYL-NAPHTHIRIDINE-3-CARBOXAMIDES AND THEIR USE
DE102015015061A8 (en) lighting device
GB2527199B (en) Recessed light fixture
LT3141006T (en) IMPROVING THE COMMUNICATION OF THE DEVICE WITH THE DEVICE
DK3412700T3 (en) RELATIONS
DE112015005147A5 (en) Optoelectronic component and lighting device
TWM489961U (en) Desk lamp device
ES1111905Y (en) MULTIVITY ADAPTER
GEAP201814327A (en) Treatment regimen tiacumicin compound
GB201420857D0 (en) Light fixture and module
TN2014000388A1 (en) منظومة فيزيائية متجانسة كهربائية ميكانيكية مغناطيسية التعليم
TN2014000354A1 (en) جهاز مبتكر لتلقيح النخيل